Selective internalisation of pep1 peptide into PDAC cells via il-13rα2
A novel therapeutic approach targeting pancreatic ductal adenocarcinoma (PDAC) using Pep1, a peptide that selectively binds to IL-13Rα2, facilitating cellular internalisation and offering potential for more effective treatments.
Overview
Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, necessitating innovative therapeutic strategies. This research focuses on Pep1, a hybrid peptide engineered to target IL-13Rα2, a receptor over-expressed in PDAC cells. Pep1 binds selectively to IL-13Rα2, promoting its internalisation and enabling targeted delivery of therapeutic agents. This method aims to provide a more effective treatment for PDAC by leveraging the receptor's over-expression for selective therapy.
Technical specifications
Pep1 is a heptamer peptide identified through phage display screening for IL-13Rα2 ligands. It is conjugated with a cytolytic peptide to form Pep1-Phor21, which demonstrates anticancer properties against IL-13Rα2-expressing cancer cells, including PDAC. The research outlines the use of whole-cell ELISA and confocal fluorescence microscopy to assess Pep1-induced internalisation of IL-13Rα2 in cell models. This process involves evaluating the effects of inhibiting various molecular pathways on the internalisation process.
Technology readiness level
The technology is currently at TRL 3, indicating that it has been experimentally validated in a laboratory setting. Further research and validation are planned to advance the development of this targeted therapeutic approach.
About Swansea University
Swansea University is a comprehensive public research university with dual campuses along Swansea Bay and a partnership-driven, applied research culture. Purpose-built facilities on the Bay Campus co-locate engineering research with company spaces and pilot-scale testbeds, accelerating product development and contract R&D. The Medical School works closely with NHS partners, with an adjacent hospital supporting clinical translation and real‑world evaluation. Research activity is backed by competitive national funding through UK Research and Innovation and Innovate UK, alongside NHS collaborations and Welsh Government support. A dedicated technology transfer office manages IP, licensing and spinout formation, with access to on‑campus collaboration and incubation space.
delivered to your inbox.